84 results on '"Barilà, G."'
Search Results
2. Topic: AS04-MDS Biology and Pathogenesis/AS04h-Immune deregulation/inflammation: STAT3 MUTATIONS IMPACT ON MDS ASSOCIATION IN PATIENTS WITH LGL LEUKEMIA (LGLL)
3. P49 A REAL-WORLD RETROSPECTIVE-PROSPECTIVE ANALYSIS OF EFFICACY AND SAFETY OF COMBINED IXAZOMIB, LENALIDOMIDE AND DEXAMETHASONE IN RELAPSED/REFRACTORY MULTIPLE MYELOMA: THE NORTHERN ITALY EXPERIENCE
4. Diffusion-weighted whole-body MRI for evaluation of early response in multiple myeloma
5. P069 - Topic: AS04-MDS Biology and Pathogenesis/AS04h-Immune deregulation/inflammation: STAT3 MUTATIONS IMPACT ON MDS ASSOCIATION IN PATIENTS WITH LGL LEUKEMIA (LGLL)
6. P600: HIGH-DEPTH RNA-SEQUENCING IDENTIFIES CD8+ STAT3 MUTATED T-LGLL PATIENTS AS A DISTINCT BIOLOGICAL ENTITY WITHIN THE DISEASE HETEROGENEITY
7. P605: T-CELL PROLYMPHOCYTIC LEUKEMIA: MOLECULAR CHARACTERIZATION OF A COHORT OF 18 PATIENTS AND EVALUATION OF BORTEZOMIB AS A POSSIBLE THERAPEUTIC STRATEGY
8. P02: PROGNOSTIC STRATIFICATION OF STANDARD RISK MULTIPLE MYELOMA DEFINED BY REVISED ISS
9. P02 - Topic: AS01-Diagnosis/AS01b-Flow cytometry: INCIDENCE AND RELEVANCE OF T-LARGE GRANULAR LYMPHOCYTES AND NK CELLS IMBALANCES IN BONE MARROW BLOOD IN MYELODYSPLASTIC SYNDROMES
10. O19 - Topic: AS04-MDS Biology and Pathogenesis/AS04h-Immune deregulation: A MULTI-CENTER EXPERIENCE OF HYPOCELLULAR MYELODYSPLASTIC SYNDROMES (H-MDS): FROM CLINICAL DESCRIPTION TO IMMUNOLOGICAL CHARACTERIZATION
11. Topic: AS01-Diagnosis/AS01b-Flow cytometry
12. Topic: AS04-MDS Biology and Pathogenesis/AS04h-Immune deregulation
13. Identification of a miR-146b-FasL axis in the development of neutropenia in T-LGL leukemia
14. TARGETED ACTIVATION OF THE PROTEIN PHOSPHATASES SHP-1 AND PP2A ABROGATES CONSTITUTIVE ACTIVATION OF SURVIVAL PATHWAYS IN LARGE GRANULAR LYMPHOCYTE LEUKEMIA (LGLL)
15. BORTEZOMIB LOWERS THE STAT3 PATHOGENETIC ROLE IN T-LGLL NEUTROPENIA DEVELOPMENT BY RESTORING MIR146B EXPRESSION
16. PF364 BORTEZOMIB LOWERS THE STAT3 PATHOGENETIC ROLE IN T-LGLL NEUTROPENIA DEVELOPMENT BY RESTORING MIR146B EXPRESSION
17. PF367 MOLECULAR EVIDENCE THAT ATOVAQUONE IS A NEW STAT3-INHIBITOR COUNTERBALANCING LEUKEMIC CELL PRO-SURVIVAL IN LARGE GRANULAR LYMPHOCYTE LEUKEMIA
18. PS1140 THE IMBALANCE OF THE NON-LEUKEMIC COMPARTMENT SUSTAINS THE LYMPHOPROLIFERATION IN T-LARGE GRANULAR LYMPHOCITYES LEUKEMIA
19. CLINICAL AND BIOLOGICAL PREDICTORS OF OUTCOME IN LARGE GRANULAR LYMPHOCYTE LEUKEMIA: A SINGLE CENTER EXPERIENCE OF 205 PATIENTS
20. PF362 A FIRST HIGH-DEFINITION LANDSCAPE OF SOMATIC MUTATIONS IN CHRONIC LYMPHOPROLIFERATIVE DISORDER OF NK CELLS
21. PS1145 TARGETED ACTIVATION OF THE PROTEIN PHOSPHATASES SHP-1 AND PP2A ABROGATES CONSTITUTIVE ACTIVATION OF SURVIVAL PATHWAYS IN LARGE GRANULAR LYMPHOCYTE LEUKEMIA (LGLL)
22. MIR146-B expression levels correlate with biological and clinical features in T-LGL leukemia
23. Lenalidomide Long-Term Neurotoxicity: Neurophysiological Follow-up Study in Patients With Relapsed/Refractory Myeloma
24. Diffusion Weighted Whole Body MRI for early evaluation of response in Multiple Myeloma
25. Identification of novel STAT5B mutations and characterization of TCRβ signatures in CD4+ T-cell large granular lymphocyte leukemia
26. Elotuzumab plus pomalidomide and dexamethasone in relapsed/refractory multiple myeloma: Extended follow-up of a multicenter, retrospective real-world experience with 321 cases outside of controlled clinical trials.
27. Daratumumab-based regimens for patients with multiple myeloma plus extramedullary plasmacytomas or paraskeletal plasmacytomas: initial follow-up of an Italian multicenter observational clinical experience.
28. A real-world retrospective-prospective analysis of efficacy and safety of combined ixazomib, lenalidomide, and dexamethasone in relapsed/refractory multiple myeloma: The northern Italy experience.
29. The constitutive activation of STAT3 gene and its mutations are at the crossroad between LGL leukemia and autoimmune disorders.
30. Elotuzumab plus pomalidomide and dexamethasone in relapsed/refractory multiple myeloma: a multicenter, retrospective, real-world experience with 200 cases outside of controlled clinical trials.
31. A real-life study of daratumumab-bortezomib-dexamethasone (D-VD) in lenalidomide exposed/refractory multiple myeloma patients: a report from the Triveneto Myeloma Working Group.
32. Not all LGL leukemias are created equal.
33. Tγδ LGLL identifies a subset with more symptomatic disease: analysis of an international cohort of 137 patients.
34. Lenalidomide-based triplet regimens in first relapsed multiple myeloma patients: real-world evidence from a propensity score matched analysis.
35. Imaging minimal residual disease evaluation in multiple myeloma using [ 18 F]FDG PET/MRI.
36. CK1α/RUNX2 Axis in the Bone Marrow Microenvironment: A Novel Therapeutic Target in Multiple Myeloma.
37. Hypocellular myelodysplastic syndromes (h-MDS): from clinical description to immunological characterization in the Italian multi-center experience.
38. Defining TCRγδ lymphoproliferative disorders by combined immunophenotypic and molecular evaluation.
39. Safety of Rapid Daratumumab Infusion: A Retrospective, Multicenter, Real-Life Analysis on 134 Patients With Multiple Myeloma.
40. Identification of novel STAT5B mutations and characterization of TCRβ signatures in CD4+ T-cell large granular lymphocyte leukemia.
41. Neutropenia and Large Granular Lymphocyte Leukemia: From Pathogenesis to Therapeutic Options.
42. Protein Kinase CK1α Sustains B-Cell Receptor Signaling in Mantle Cell Lymphoma.
43. Treatment Induced Cytotoxic T-Cell Modulation in Multiple Myeloma Patients.
44. Subcutaneous immunoglobulins replacement therapy in secondary antibody deficiencies: Real life evidence as compared to primary antibody deficiencies.
45. A real-world efficacy and safety analysis of combined carfilzomib, lenalidomide, and dexamethasone (KRd) in relapsed/refractory multiple myeloma.
46. The Importance of Alliance between Hematologists and Dentists: A Retrospective Study on the Development of Bisphosphonates Osteonecrosis of the Jaws (Bronj) in Multiple Myeloma Patients.
47. Lack of Viral Load Within Chronic Lymphoproliferative Disorder of Natural Killer Cells: What Is Outside the Leukemic Clone?
48. Drug Conjugated and Bispecific Antibodies for Multiple Myeloma: Improving Immunotherapies off the Shelf.
49. Actionable Strategies to Target Multiple Myeloma Plasma Cell Resistance/Resilience to Stress: Insights From "Omics" Research.
50. Identification of a miR-146b -Fas ligand axis in the development of neutropenia in T large granular lymphocyte leukemia.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.